ArticleScientific reports2026

Predictors of severe immune-related adverse events during first-line immune checkpoint inhibitor therapy for advanced non-small cell lung cancer.

Olajumoke A Olateju et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.